gimli
BIOCON stock analysis context
BIOCON. Stock Context for AI Screening
BIOCON LIMITED. is a mid-cap stock in Healthcare. This page summarizes key screening signals for BIOCON., including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about BIOCONPrice
₹430.25
1M return
+20.25%
3M return
+12.06%
Market cap
₹69,671.73 cr
PE
180.68
ROE
+1.46%
RSI
75.78
Turnover
₹162.53 cr
Why it can matter in screens
- Momentum: BIOCON is above 50DMA, above 200DMA; RSI is 75.78.
- Returns: 1M +20.25%, 3M +12.06%, 6M +8.42%.
- Liquidity: latest turnover is ₹162.53 cr.
- Valuation: PE 180.68, PB 1.90, ROE +1.46%, ROCE +3.28%.
- Growth: 3Y sales CAGR +23.32%, 3Y profit CAGR +16.04%.
Try these prompts
- Analyze BIOCON. with valuation, momentum and industry peers
- Compare BIOCON with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare BIOCON with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.